Proteomics

AgriTech
Bioprocessing
Pharmaceuticals
Proteomics
Synthetic Biology

Multiply Labs is revolutionizing cell therapy production with ai

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins.

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins, cutting costs by up to 70%, increasing throughput, and reducing contamination ri

The Biotech Times Editorial Team  · 
Proteomics
Diagnostics
Biologics

Alamar Biosciences platform underpins Lancet Neurology lecanemab study

A Washington University cohort study used Alamar's 130-protein plasma panel to show amyloid clearance and cognitive response reflect distinct biological processes.
A Washington University cohort study used Alamar's 130-protein plasma panel to show amyloid clearance and cognitive response reflect distinct biological processes.
The Biotech Times Editorial Team  · 
Proteomics
Bioinformatics

Seer hits 100 peer-reviewed publications for Proteograph platform

Seer's Proteograph Product Suite has featured in over 100 peer-reviewed studies, spanning disease biology, ageing and population-scale biomarker discovery.
Seer's Proteograph Product Suite has featured in over 100 peer-reviewed studies, spanning disease biology, ageing and population-scale biomarker discovery.
The Biotech Times Editorial Team  · 
Proteomics
Diagnostics

Seer wins EPO patent ruling and secures ITC probe into Nanomics

Seer has defended a key European proteomics patent and launched a US trade investigation targeting Nanomics' competing Proteonano products.
Seer has defended a key European proteomics patent and launched a US trade investigation targeting Nanomics' competing Proteonano products.
The Biotech Times Editorial Team  · 
Proteomics
Regulatory Science

Mineralys presents lorundrostat HF biomarker data at ENDO 2026

Proteomic analysis of over 1,000 trial participants found lorundrostat reduced six of eleven heart failure risk biomarkers, including NT-proBNP.
Proteomic analysis of over 1,000 trial participants found lorundrostat reduced six of eleven heart failure risk biomarkers, including NT-proBNP.
The Biotech Times Editorial Team  · 
Subscribe to Proteomics